CPhI Online

- Biopharma News

Alvotech and DKSH extend biosimilar partnership in Asia

22 Sep 2020

The companies will commercialize six new biosimilar candidates addressing multiple therapeutic areas.

Alvotech and DKSH, a healthcare provider across 36 emerging countries in South-East Asia, have agreed to expand their strategic partnership to commercialize six new biosimilar product candidates for the Asian markets.

The initial pipeline contains biosimilar candidates addressing multiple therapeutic areas.

In March 2020, the companies announced its exclusive partnership agreement for AVT02, a biosimilar monoclonal antibody to AbbVie’s HUMIRA, which is a leading drug indicated for the treatment of several autoimmune diseases, including rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease amongst other indications.

The collaboration includes the following markets: Taiwan, Korea, Hong Kong, Philippines, Vietnam, Thailand, Cambodia, Myanmar, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan.

These biosimilar candidates’ brand values are estimated around US$1.5 billion in annual sales in the Asia Pacific region, according to IQVIA data.

In the last 12 months, Alvotech has made notable strategic partnership agreements with leading regional and global industry players including: Teva in the US, Stada in Europe, JAMP in Canada, Yas Holding in the Middle East and Fuji Pharma in Japan.

Related Categories

Related Content